HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy

Authors:

Abstract
No abstract available
Funding Information
  • Foundation for Liver and Gastrointestinal Research
  • Fujirebio Europe NV

This publication has 12 references indexed in Scilit: